Next Issue
Volume 8, 01
Previous Issue
Volume 7, 11
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.4
Journals
Cardiovascular Medicine
Volume 7
Issue 12
cardiovascmed-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 7, Issue 12 (12 2004) – 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
2 pages, 149 KB  
Interesting Images
Ischémie Mésentérique et Thrombi Aortiques
by Jean-Yves Delaite, Dominique Didier and Cédric Vuille
Cardiovasc. Med. 2004, 7(12), 466; https://doi.org/10.4414/cvm.2004.01061 - 29 Dec 2004
Viewed by 41
Abstract
Une patiente de septante... Full article
►▼ Show Figures

Figure 1

1 pages, 150 KB  
Interesting Images
Syndrome de Pré-Excitation
by Jürg Schläpfer
Cardiovasc. Med. 2004, 7(12), 465; https://doi.org/10.4414/cvm.2004.01064 - 29 Dec 2004
Viewed by 38
Abstract
Jeune homme de 30... Full article
►▼ Show Figures

Figure 1

5 pages, 176 KB  
Editorial
Diagnostischer Einsatz der Natriuretischen Peptide
by Christian Müller, Hans-Peter Brunner La-Rocca and Peter Buser
Cardiovasc. Med. 2004, 7(12), 459; https://doi.org/10.4414/cvm.2004.01062 - 29 Dec 2004
Viewed by 41
Abstract
B-type natriuretic peptide (BNP) and NTproBNP are currently the most prominent members of the natriuretic peptide family. These markers are reliably elevated in patients with congestive heart failure (CHF). Accordingly, they are used increasingly in the diagnosis of patients with acute dyspnea, for [...] Read more.
B-type natriuretic peptide (BNP) and NTproBNP are currently the most prominent members of the natriuretic peptide family. These markers are reliably elevated in patients with congestive heart failure (CHF). Accordingly, they are used increasingly in the diagnosis of patients with acute dyspnea, for risk stratification and therapeutic monitoring in patients with established CHF, as well as in patients with acute coronary syndrome. Full article
►▼ Show Figures

Figure 1

6 pages, 314 KB  
Article
Wie Erfolgreich Ist Die Ambulante Elektrokonversion des Therapieresistenten Vorhofflimmerns?
by Gregor Zajec, Rosy Hug, Thomas F. Lüscher and Juraj Turina
Cardiovasc. Med. 2004, 7(12), 453; https://doi.org/10.4414/cvm.2004.01063 - 29 Dec 2004
Viewed by 43
Abstract
Between 1993 and 1997 in our out-patient clinic, a 135 direct current electrical cardioversions were performed in 88 patients with atrial fibrillation resistant to medical therapy. Cardioversion was done in short general anaesthesia with propofol (87%) or etomidate (13%). The pads were placed [...] Read more.
Between 1993 and 1997 in our out-patient clinic, a 135 direct current electrical cardioversions were performed in 88 patients with atrial fibrillation resistant to medical therapy. Cardioversion was done in short general anaesthesia with propofol (87%) or etomidate (13%). The pads were placed antero-posterior, a monophase shock energy of a mean 148 Joule was applied. Neither during cardioversion nor during 4 hours observation in the hospital serious complications ensued. Primary success, conversion to sinus rhythm, was achieved in 93% of cardioversion; within the 12 hours after cardioversion atrial fibrillation recurred in 11% of cases. In sinus rhythmus remained at 6, 12, 24, and 36 months 48%, 33%, 22% and 17% of the patients, respectively. Somewhat higher proportion of sinus rhythmus was found in 88 cases with the first cardioversion – at 6, 12, 24 and 36 months 54%, 40%, 27% and 27% of the patients, respectively. In univariate analysis previous atrial fibrillation episodes (p = 0.0075), previous cardioversion (p = 0.0137), digoxin before cardioversion (p = 0.0097), left atrium enlargement (>4.0 cm; p = 0.054), higher shock energy in Joule (p = 0.0021) and >1 shock (p = 0.0017) were correlated with atrial fibrillation recurrence during the follow-up. In multivariate Cox analysis left atrium size >4.0 cm (p = 0.023; RR = 0.26) and higher shock energy in Joule (p = 0.0082; RR = 1.006) were independent predictors of atrial fibrillation recurrence. Cardioversion can be performed ambulatory without major complications and is initial successful in >90% of drug resistant atrial fibrillation. Previous atrial fibrillation episodes, previous cardioversion, enlarged left atrium and high shock energy applied herald recurrence of atrial fibrillation in the follow-up. Short-term results can be improved by amiodarone and diuretics/ACE-blockers therapy in cases of heart failure. Long-term results of cardioversion are disappointing while only about 50% of the patients remains in sinus rhythmus after 6 months and even only 25% after 24 months. Full article
►▼ Show Figures

Figure 1

10 pages, 182 KB  
Article
Kosteneffektivität von Perindopril bei Patienten Mit Koronarer Herzkrankheit in der Schweiz-Eine Analyse der EUROPA-Studie
by Thomas D. Szucs and Roger Darioli
Cardiovasc. Med. 2004, 7(12), 443; https://doi.org/10.4414/cvm.2004.01060 - 29 Dec 2004
Viewed by 51
Abstract
Background: The efficacy of therapy for coronary heart disease with ACE inhibitors has been documented in clinical investigations. The EUROPA study has backed up the clinical usefulness of the ACE inhibitor perindopril in a dose of 8 mg/day in patients with stable coronary [...] Read more.
Background: The efficacy of therapy for coronary heart disease with ACE inhibitors has been documented in clinical investigations. The EUROPA study has backed up the clinical usefulness of the ACE inhibitor perindopril in a dose of 8 mg/day in patients with stable coronary heart disease without cardiac failure. This provides an opportunity of evaluating the cost-effectiveness of this therapy in the context of the Swiss healthcare system. Patients and methods: The cost-effectiveness of perindopril was evaluated on the basis of EUROPAstudy results by incremental costeffectiveness analysis. All costs were evaluated from the viewpoint of compulsory sickness insurance. Effectiveness was computed as life years gained, using epidemiological modelling. Costs and effectiveness were subjected to univariate sensitivity analysis. Results: The incremental costs amount to CHF 1684 (1108 euro) in the group treated with perindopril. Life years gained by the therapy (mean duration 4.2 yr) amount to 0.167 per patient. The resultant cost effectiveness of perindopril therapy in Switzerland amounts, discounted, to CHF 10 086 (6636 euro) per life year gained. The soundness of this result was backed by an extensive sensitivity analysis, with costs of CHF 5758 (3788 euro) to CHF 16 809 (11 059 euro) per life year saved. Conclusion: Administration of 8 mg perindopril in patients with stable coronary heart disease in Switzerland shows a comparatively favourable cost-effectiveness ratio. Full article
10 pages, 345 KB  
Proceeding Paper
Telomere Biology in Cardiovasular Disease
by David J. Kurz
Cardiovasc. Med. 2004, 7(12), 433; https://doi.org/10.4414/cvm.2004.01065 - 29 Dec 2004
Viewed by 48
Abstract
Advanced age brings about significant changes to cardiovascular physiology, and is an independent risk factor for the development of atherosclerosis. The basis for this association remains unclear, but it has been suggested that atherogenesis may share common mechanisms with the ageing process. Ageing [...] Read more.
Advanced age brings about significant changes to cardiovascular physiology, and is an independent risk factor for the development of atherosclerosis. The basis for this association remains unclear, but it has been suggested that atherogenesis may share common mechanisms with the ageing process. Ageing at the cellular level leads to a condition known as replicative senescence, which is triggered by the shortening of chromosomal telomeres during repeated cell division. Senescent endothelial cells show a number of features, which could contribute to the initiation or progression of the atherosclerotic plaque, such as loss of regenerative capacity and increased expression of pro-atherogenic proteins. This review will outline the current understanding of telomere function and summarise the evidence supporting a role for senescence-driven pathophysiology of vascular cells in age-related cardiovascular disease. This will include published work from vascular cell culture, animal experiments and observational studies in humans. Full article
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Previous Issue
Next Issue
Back to TopTop